After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

For the first time, pharmacists in the US will be able to substitute a cheaper biosimilar version when they receive a prescription for AbbVie’s high-concentration formulation of Humira ...

After hours: 29 November at 16:53 GMT-5 ...

After hours: November 29 at 4:53 p.m. EST ...